Table 2.
Transplant outcome, CMV infection and treatment
| Number of patients | UD | HAPLO | p-value |
|---|---|---|---|
| 30 | 67 | ||
| Acute GvHD II–IV | 9 (30%) | 16 (24%) | 0.5 |
| Day of CMV infection | 33 (3–132) | 27 (1–665) | 0.4 |
| Antigenemia vs PCR | 18 vs 12 | 58 vs 9 | 0.003 |
| Duration of Foscarnet Tx | 13 (2–91) | 14 (2–71) | 0.9 |
| 1st vs 2nd or 3th line | 21 vs 9 | 41 vs 26 | 0.4 |
| Alone vs association | 27 vs 3 | 57 vs 10 | 0.5 |
| Response to foscarnet | 59% (43–81%) | 84% (74–95%) | 0.01 |
| Time to CMV clearance (days) | 16 (1–47) | 9 (1–94) | 0.1 |
| PB counts at CMV infections | |||
| WBC <1 × 109/L | 25 (83%) | 45 (69%) | 0.1 |
| Lymphocytes ×109/La | 0.4 (0.05–4.9) | 0.9 (0–11.5) | 0.05 |
| Hb <10 gr/dl | 25 (83%) | 45 (69%) | 0.1 |
| Platelets <20 × 109/L | 11 (37%) | 20 (31%) | 0.5 |
| Foscarnet 1st line | 19 (63%) | 39 (58%) | 0.8 |
| PB Lymph. ×109/L postb | 1.04 (0.04–6.8) | 1.7 (0.05–7) | 0.02 |
| Transplant-related mortality | 34% (20–56%) | 22% (12–39%) | 0.1 |
| Actuarial survival at 3 years | 51% (33–70%) | 71% (58–84%) | 0.02 |
| Causes of death | 0.07 | ||
| Graft failure | 1 | 1 | |
| Toxicity | 5 (17%) | 4 (6%) | |
| GvHD | 1 | 1 | |
| Infections | 2 (7%) | 5 (7%) | |
| Relapse | 5 (17%) | 4 (6%) | |
| Follow-up days | 446 (64–1808) | 483 (43–1630) | 0.9 |
The peripheral lymphocyte count is reported at the time of firsta and lastb foscarnet dose
Abbreviations as in Table 1